In acute promyelocytic leukemia (APL) low BAALC gene expression identifies a patient group with favorable overall survival and improved relapse free survival

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 378-382

  Nolte, Florian ^a   Hecht, Anna ^a   Reinwald, Mark ^a   Nowak, Daniel ^a   Nowak, Verena ^a   Hanfstein, Benjamin ^a   Faldum, Andreas ^b   Büchner, Thomas ^b   Spiekermann, Karsten ^c   Sauerland, Cristina ^b   Hofmann, Wolf Karsten ^a   Lengfelder, Eva ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Acute promyelocytic leukemia; BAALC; Overall survival; Prognosis; Relapse free survival; Risk stratification

Indexed keywords

CYTARABINE; DAUNORUBICIN; MITOXANTRONE; RETINOIC ACID; TIOGUANINE;

ADULT; AGED; ARTICLE; BAALC GENE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE;

ADULT; AGED; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL;

EID: 84875381732     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.018     Document Type: Article

References (16)

1. Sanz M.A., Lo Coco F., Martin G., Avvisati G., Rayon C., Barbui T., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96(August (4)):1247-1253.
2. Lengfelder E., Haferlach C., Saussele S., Haferlach T., Schultheis B., Schnittger S., et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009, 23(December (12)):2248-2258.
3. Burnett A.K., Grimwade D., Solomon E., Wheatley K., Goldstone A.H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999, 93(June (12)):4131-4143.
4. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94(August (4)):1192-1200.
5. Sanz M.A., Martin G., Rayon C., Esteve J., Gonzalez M., Diaz-Mediavilla J., et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999, 94(November (9)):3015-3021.
6. Sanz M.A., Martin G., Gonzalez M., Leon A., Rayon C., Rivas C., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103(February (4)):1237-1243.
7. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100(December (13)):4298-4302.
8. Baldus C.D., Tanner S.M., Ruppert A.S., Whitman S.P., Archer K.J., Marcucci G., et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003, 102(September (5)):1613-1618.
9. Baldus C.D., Thiede C., Soucek S., Bloomfield C.D., Thiel E., Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol 2006, 24(February (5)):790-797.
10. Baldus C.D., Martus P., Burmeister T., Schwartz S., Gokbuget N., Bloomfield C.D., et al. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 2007, 25(August (24)):3739-3745.
11. Langer C., Radmacher M.D., Ruppert A.S., Whitman S.P., Paschka P., Mrozek K., et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 2008, 111(June (11)):5371-5379.
12. Kuhnl A., Gokbuget N., Stroux A., Burmeister T., Neumann M., Heesch S., et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 2010, 115(May (18)):3737-3744.
13. Lengfelder E., Hanfstein B., Haferlach C., Braess J., Krug U., Spiekermann K., et al. Front line treatment of elderly patients with acute promyelocytic leukemia: long-term results of the German AML Cooperative Group. ASH Annu Meet Abstr 2011, 118(November (21)):425-430.
14. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29(May (9)):e45.
15. Heesch S., Schlee C., Neumann M., Stroux A., Kuhnl A., Schwartz S., et al. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia 2010, 24(August (8)):1429-1436.
16. Xu B., Chen G., Shi P., Guo X., Xiao P., Wang W., et al. shRNA-Mediated BAALC knockdown affects proliferation and apoptosis in human acute myeloid leukemia cells. Hematology 2012, 17(January (1)):35-40.